Loading…
The patent was issued on July 14, 2025.
Avalon GloboCare Corp. (ALBT) announced that it has been granted a patent for its CAR-T and CAR-NK cell technology. The patent, issued on July 14, 2025, covers innovative methods and compositions for the treatment of various diseases using these cell therapies.
The company did not provide specific financial details or comparisons related to this patent issuance. The patent is expected to strengthen Avalon GloboCare's intellectual property portfolio and support its ongoing research and development efforts in the field of cell therapy.
As of the latest available data, Avalon GloboCare Corp. has a free float of 3,722,800 shares and 4,252,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.